top of page

NovaSpira Biotherapeutics 
First-in-Class T‑Cell & Immune Cell Holistic Activator

Doctor Using Tablet

NovaSpira Biotherapeutics is a U.S.-based biotech company developing bispecific T-cell & immune cell activator therapy for GPC3-positive solid tumors, including liver & lung cancers. The lead candidate, BOS‑342, is currently in Phase 1 clinical development.

About Us

 

a3.png


Han Li
Co-Founder and Chief Executive Officer

Han's 28-year  experience spans finance, strategy, and science across leading organizations. He served as CFO at Ascentage Pharma, held business development and strategy roles at Bayer, and conducted research at Genentech. Earlier in his career, he worked as a biotechnology analyst at Morgan Stanley and SunTrust
 

Han Li

Han Li, Ph.D., MBA

Co-Founder and CEO


Jason Huang
Co-Founder 

Jason has extensive experience in oncology clinical development, with a focus on the design, execution, and oversight of clinical trials across multiple stages of development. He previously served as Chief Medical Officer at XlifeSciences and Fosun. His background includes leading oncology clinical development efforts at Ascentage Pharma, GSK, Bristol Myers Squibb, and Novartis, with experience spanning global clinical programs and translational strategy.

image2.png

Jason Huang, M.D.

Co-Founder

Han Li


Min Ding
Co-Founder

Min has more than 25 years of experience in business and intellectual property law. His career spans roles at law firms and within the healthcare industry. He holds a J.D. from Columbia Law School

image3.png

Min Ding, Ph.D., J.D.

Co-Founder

Our Investors

image.png

BOS-342, a First-in-Class GPC3x4-1BB Bispecific T-cell &Immune cell Activator

BOS-342 is a fully human bispecific T-cell & immune cell activator generated using anticalin fusion protein technology. It binds to and activates the co-stimulatory immune cell receptor 4-1BB (CD137) when also binding to the tumor cell antigen GPC3

image.png

Anticalin Technology

Anticalin proteins are comprised of a four-loop variable region and a rigidly conserved beta-barrel backbone, which

together, form a pliable cup-like binding pocket.

Structure

image.png

Anticalin proteins contain rationally diversified amino acids while maintaining the integrity of the lipocalin structure, providing a coveted specificity and affinity against a broad spectrum of targets and durability that allows for flexibility of formulation and delivery.

Stable and Monovalent

image.png

Originally developed by Pieris Pharmaceuticals, anticalin technology can genetically fuse Anticalin proteins with antibodies to create bi- and multi-specific drug candidates.

Bi & Multispecific Approaches

image.png
image.png

  • Glypican 3 (GPC3) is a tumor-associated antigen that is specifically expressed in many cancers, including liver, squamous lung, and gastric cancers.

​

  • 4-1BB (CD137) is an inducible co-stimulatory receptor expressed on activated immune T cells, NK, dendritic cells, monocytes, and neutrophils.​

​

  • 4-1BB-targeting TCE delivers prolonged, enduring anti-tumor immune responses, ideal for long-term tumor control. 

Preclinical Data Summary

​

  • In vitro binding assays

    • BOS-342 binds 4-1BB and GPC3 with high affinity and specificity

    • BOS-342 binds to 4-1BB and GPC3 simultaneously

  • In vitro functional assays

    • BOS-342 induces potent dose-dependent T-cell activation and tumor cell killing only in the presence of GPC3 expression​

  • BOS-342 is efficacious in vivo

    • BOS-342 inhibits turior growth in an HCC humanized mouse model

    • BOS-342 leads to dose-dependent increases in CD3+ and CD8+ T-cell tumor infiltration

  • Tumor-selective 4-1BB agonism of BOS-342 allows maximum local activation of 4-1BB for tumor cell killing with minimal risk of side effects 

Screenshot 2026-01-04 at 8.13_edited.jpg

Clinical Development

  • Early Phase I data advanced liver cancer show: 

    • a manageable safety profile​​

    • signals of antitumor efficacy (durable response observed)

  • Plan to initiate Phase Ib/PoC study in GPC3+ solid tumors

bottom of page